Skip to main content

Table 3 Efficacy analysis

From: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

  Phase 2 Validation
14 days intention-to-treat   
No. of events/no. of patients at risk 55/299 101/884
Lethality rate, % (97.5% CI) 18.4% (13.6–24.0) 11.4% (9.1–14.0)
P value (P0 = 20%) 0.52  < 0.001
14 days modified intention-to-treat   
No. of events/no. of patients at risk 28/180 56/515
 Lethality rate, % (95% CI) 15.6% (10.6–21.7) 10.9% (8.3–13.9)
30 days intention-to-treat   
No. of events/No. of patients at risk 67/299 158/858
 Lethality rate, % (97.5% CI) 22.4% (17.2–28.3) 18.4% (15.5–21.6)
 P value (P0 = 35%)  < 0.001  < 0.001
 Median time of death, days (IQR) 8 (4–14) 11 (4–18)
30 days modified intention-to-treat   
No. of events/no. of patients at risk 36/180 99/495
 Lethality rate, % (95% CI) 20.0% (14.4–26.6) 20.0% (16.6–23.8)